DMRA Company Profile and Key Details

Average 10-day trading volume of 570.12 thousand shares is in line with the 3-month average of 556.96 thousand, indicating normal recent market interest.

Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $45.00 to $35.00. The high target offers 60.71% upside. The low target suggests 25.0% downside. The mean target is $38.75. This offers 38.39% upside. Damora Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by 59.89%. The prior quarter beat by 2216.35%. Over the last six quarters, Apple has recorded several small beats. These include 2216.35% in March 18, 2026.

Valuation shows Damora Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.16. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $38.75, suggesting 38.39% upside. Our AI forecast model points to short-term strength (21.93% over two weeks), a medium-term fall (-1.96% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Damora Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 21.93%, with price expected at $34.14 by July 27, 2026, within a range of $32.44 to $35.84 3-Month Outlook: Projected fall of -1.96%, reaching $27.45 by October 08, 2026, with a range of $27.23 to $27.65. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by July 13, 2027, within a range of $0.00 to $0.00.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Damora Therapeutics, Inc. (NASDAQ:DMRA) closed at $28.00 USD, losing -$0.53 (-1.86%) from the previous close of $28.53. The stock is currently mid-range between its 52-week high and low $2.45 and $38.33. With a market capitalization of about $1.72 billion, Damora Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.47). Key stats such as the average daily volume over the past year has been around 547.55 thousand shares, volume is running light vs its 52-week average. Headquartered in Waltham, MA, Damora Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jennifer A. Jarrett, the company employs approximately 7 people and listed since March 10, 2026. Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics.

Damora Therapeutics, Inc. trades at a P/E ratio of -0.16, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.07 suggesting the stock is closer to book value. The P/FCF stands at -85.82, also below market averages.